Now Playing
Opinion|Videos|October 4, 2024
The Power of Partnership: Enhancing Patient Care in Multiple Myeloma through Academic and Community Physician Collaboration
Panelists discuss how effective collaboration, care coordination, and communication between academic and community physicians are crucial for ensuring seamless transitions and high-quality care for patients with multiple myeloma.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Let’s talk about the importance of collaboration in patient care between an academic and community physician when transitioning care for patients with multiple myeloma.
- How do you coordinate, care for and maintain communication?
- How can you ensure centers are equipped to receive patients back?
Advertisement
Related to this article
Hans C. Lee, MD, discussed how community oncologists with limited access to MRD testing can think about the new IMS/IMWG definition of cure in myeloma.
Hans C. Lee, MD, discussed how he monitors patients with multiple myeloma who achieve deep, sustained MRD negativity after coming off therapy.
![“[W]e should strive to increase the [number] of patients…who enjoy long-term disease-free survival and possibly cure,” said Meletios Dimopoulos, MD.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/c7abebf9344f9b1be9aee80d9879d139c1655bcc-1200x1197.jpg?w=350&fit=crop&auto=format)
“[W]e should strive to increase the [number] of patients…who enjoy long-term disease-free survival and possibly cure,” said Meletios Dimopoulos, MD.
Pieter Sonneveld, MD, PhD, explained how sustained MRD negativity with DVRd in the PERSEUS trial may guide long-term outcome counseling in multiple myeloma.
Hematologic specialists discussed where ciltacabtagene autoleucel fits in the treatment paradigm at first relapse and beyond in multiple myeloma.
Updated NCCN Guidelines for multiple myeloma add a dedicated MRD testing framework and expand recommended MRD assessment timepoints.
Advertisement
Advertisement
Trending on CancerNetwork
1
Neoadjuvant Radiation May Improve Tolerability in Cholangiocarcinoma
2
Distal Extrahepatic Cholangiocarcinoma May Gain From Neoadjuvant Radiation
3
Hydrogel Spacer Receives FDA 510(k) Clearance for Prostate Cancer Radiotherapy
4
How Oncologists Can Navigate Patient Requests for Medical Aid in Dying
5